A novel NR5A1 variant in an infant with elevated testosterone from an Australasian cohort of 46,XY patients with disorders of sex development. by Wu, JY et al.
O R I G I N A L A R T I C L E
A novel NR5A1 variant in an infant with elevated testosterone
from an Australasian cohort of 46,XY patients with disorders of
sex development
Joyce Y. Wu*,††, Ivan N. McGown*, Lin Lin†, John C. Achermann†, Mark Harris‡,‡‡, David M. Cowley*,††,‡‡,
Salim Aftimos§, Kristen A. Neville¶, Catherine S. Choong** and Andrew M. Cotterill‡,††
*Department of Clinical Chemistry, Mater Hospital, South Brisbane, QLD, Australia, †Developmental Endocrinology Research
Group, Clinical and Molecular Genetics Unit, University College London Institute of Child Health, University College London,
London, UK, ‡Department of Paediatric Endocrinology, Mater Children’s Hospital, South Brisbane, QLD, Australia, §Northern
Regional Genetics Service, Auckland Hospital, Auckland, New Zealand, ¶Department of Endocrinology, Sydney Children’s Hospital,
Randwick, NSW, **Department of Endocrinology and Diabetes, Princess Margaret Hospital for Children, School of Paediatrics and
Child Health, University of Western Australia Subiaco, WA and †† University of Queensland, Brisbane, ‡‡ Mater Medical Research
Institute, South Brisbane, QLD, Australia.
Summary
Background NR5A1 loss-of-function mutations are increasingly
found to be the cause of 46,XY disorders of sex development
(DSD).
Objective To determine the presence of NR5A1 mutations in
an Australasian cohort of 17 46,XY DSD patients with presumed
androgen insensitivity syndrome (AIS) who were negative for
androgen receptor gene (AR) mutation.
Design Exons 2-7 of NR5A1 were PCR amplified and
sequenced. Gene expression and cellular localization studies were
performed on a novel NR5A1 variant c.74A>G (p.Y25C) identi-
fied in this study.
Results We identified one novel mutation, c.74A>G (p.Y25C)
in a patient characterized by penoscrotal hypospadias with bifid
scrotum. He had elevated testosterone and gonadotropins in
early infancy. Functional analysis of p.Y25C in vitro demon-
strated reduced transcriptional activation by SF-1 and partially
impaired nuclear localization in a proportion of transfected
human adrenal NCI-H295R cells.
Conclusion This is the first reported case of a DSD patient
with a NR5A1 mutation and elevated testosterone levels. Our
finding supports evaluation of NR5A1 mutations in 46,XY DSD
patients with a range of testosterone levels.
(Received 6 June 2012; returned for revision 09 July 2012; finally
revised 08 August 2012; accepted 8 August 2012)
Introduction
Disorders of sex development (DSD) encompass all the congeni-
tal conditions in which development of chromosomal, gonadal
or anatomic sex is atypical. One in 4500 births requires genetic
and endocrine studies because of abnormalities of their external
genitalia. Definitive diagnosis is made in only 50% of 46,XY
children with DSD.1
Recently, several investigators have reported heterozygous loss-
of-function mutations in the nuclear receptor subfamily five
group A member 1 gene (NR5A1) in patients with clinical fea-
tures of androgen insensitivity syndrome (AIS) but without
androgen receptor gene (AR) mutations.2 Mutations in AR, which
is located on chromosome Xq11-q12, is responsible for AIS. The
detection rate for AR mutations in Complete AIS (CAIS) range
from 667% to 83%, whereas for Partial AIS (PAIS) patients, the
detection rate for AR mutations range from 136% to 28%.3,4 AIS
is characterized by a clinical spectrum ranging from phenotypi-
cally female patients (CAIS) to decreased virilization (PAIS) in
46,XY individuals with normal or elevated androgen levels.5
The NR5A1 gene is mapped to 9q33 and consists of seven ex-
ons spanning approximately 30 kb. Exon 1 is untranslated. It
encodes Steroidogenic Factor-1 (SF-1) also known as Adrenal
4-Binding Protein (Ad4BP). SF-1 is a 461 amino acid protein
belonging to the NR5A subfamily of nuclear receptors. It is a
transcription factor that binds to specific DNA sequences in tar-
get genes and regulates transcription.6 The target genes are
expressed throughout the hypothalamic-pituitary–adrenal/gona-
dal axis and include the steroid hydroxylase genes, luteinizing
hormone receptor, adrenocorticotrophin receptor, StAR protein
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and SOX9.6,7 Thus, SF-1 has a central role in regulating adrenal
development, gonadal determination and differentiation and in
the hypothalamic-pituitary control of reproduction and
metabolism.6
In XY mice with homozygous NR5A1 deletions, there is
impaired adrenal development, complete testicular dysgenesis
with Mu¨llerian structures and female external genitalia. Two
human patients with these clinical features and NR5A1 muta-
tions have been reported.8,9 Varying degrees of functional
impairment in SF-1 can be associated with a wide range of
reproductive phenotypes without adrenal involvement, extending
from ambiguous genitalia, hypospadias to male infertility.2,10–13
We evaluated the presence of NR5A1 mutations in an Austral-
asian cohort of 17 46,XY DSD patients with presumed AIS who
were negative for AR mutations.
Materials and methods
Patients
NR5A1 testing was performed in a cohort of 17 patients who
had presumed androgen insensitivity syndrome but who were
negative for AR mutations. Six of these patients have been previ-
ously reported.3 Of the 17 patients, 15 were diagnosed with
PAIS and two with CAIS.
Molecular analysis of NR5A1
Molecular testing was performed at the National Association of
Testing Authorities (NATA) accredited Molecular Laboratory,
Mater Pathology, Mater Health Services, Brisbane, QLD.
Oligonucleotide primers were designed with Primer 3 software
(http://frodo.wi.mit.edu/primer3/primer3_code.html) and checked
for the presence of SNPs using the SNPCheck2 program
(https://ngrl.manchester.ac.uk/SNPCheckV2/snpcheck.htm). Primer
sequences are available on request.
Genomic DNA was extracted from peripheral blood leuco-
cytes, and exons 2-7 of the NR5A1 gene were amplified using a
GC-Rich PCR system (Roche/Boehringer Mannheim, Mann-
heim, Germany). PCR products were then purified with the
High Pure PCR Product Purification Kit (Roche/Boehringer
Mannheim) and sequenced using the Big Dye Terminator V31
Cycle Sequencing Kit (Applied Biosystems, Scoresby, vic., Aus-
tralia). Sequences were read on an ABI 3130xl Genetic Analyser
(Applied Biosystems) at the Griffith University Sequencing Facil-
ity (Griffith University, Nathan, QLD, Australia). All sequences
were compared with consensus sequences for NR5A1 genomic
and mRNA sequences. DNA mutation numbering is based on
GenBank reference DNA sequence NM_0049594, with the A of
the ATG initiation codon designated +1 (www.hgvs.org/mutno-
men).
Transient gene expression assays
An expression vector containing the p.Y25C change was gener-
ated by site-directed mutagenesis (QuikChange, Stratagene,
Amsterdam, the Netherlands) using wild-type (WT) pCMXSF-1
as a template. Transient transfection studies were performed in
96-well plates using tsa201 human embryonic kidney cells. These
cells do not express SF-1 and have been used widely in studies
of SF-1 function in the past.9,11,12 Empty (), WT or mutant
SF-1 expression vectors (2 ng/well; p.G35E, p.Y25C) were
co-transfected with the SF-1-responsive minimal promoter of
Cyp11a linked to luciferase (100 ng/well) using lipofectamine
2000 (Invitrogen, Paisley, UK). Cells were lysed 24 h later and
assayed for luciferase activity (Dual Luciferase Reporter Assay
system, Promega; FLUOstar Optima, BMG Labtech, Aylesbury,
UK), with standardization for Renilla co-expression.
Studies of cellular localization
A p.Y25C mutant GFP-SF-1 construct was generated by site-
directed mutagenesis in a pAcGFP-C1 vector (Clontech, Oxford,
UK) to produce a mutant fusion protein with a GFP tag at the
amino-terminus of SF-1. Empty (), WT and mutant p.Y25C
pAcGFP-C1SF-1 expression vectors (08 lg) were transfected
into SF-1 expressing NCI-H295R human adrenal cells. After
24 h, cells were fixed and counterstained with Vectashield con-
taining DAPI (Vector Laboratories, Peterborough, UK). Images
were taken on a confocal microscope.
Reproductive hormone assays
Testosterone was analysed on the Spectria Testosterone RIA
coated tube (Orion Diagnostica, Finland). Dihydrotestosterone
was assayed using an in-house RIA after extraction and partition
chromatography. LH and FSH were analysed on Immulite 2000
(Bio-Mediq DPC Pty Ltd, Los Angeles, CA, USA).
Results
Mutation analysis of patients
Molecular analysis revealed four patients to be heterozygous for
a c.437G>C (p.G146A) sequence variant and one patient to be
heterozygous for a c.74A>G (p.Y25C) sequence variant.
The c.437G>C sequence variant is a previously described vari-
ant located in the hinge region.7,14 Some consider it a polymor-
phism as previous p.G146A in vitro functional studies have
demonstrated unaltered SF-1 transactivation activity.15 There-
fore, these patients will not be further discussed in this study.
The c.74A>G is a novel variant that has not been found in
previous studies of controls.13 This change results in an amino
acid change from a highly conserved tyrosine to cysteine at
codon 25 (p.Y25C). This amino acid is situated in the first zinc
finger DNA-binding domain (See Fig. 1). This appears to be a
de novo change as both parents are phenotypically normal and
were found to be negative for this variant.
The proband was the first child for the couple. He was born
at 41 + 1 week following an uneventful pregnancy. At birth, he
had penoscrotal hypospadias with a small phallus (20 mm long),
chordee, a ventrally deficient prepuce, bifid scrotum and two
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scrotal testes. His pelvic and renal ultrasound demonstrated
05–1 ml testes bilaterally in the scrotum with normal kidneys
bilaterally and no Mu¨llerian structures. Hormone results shortly
after birth showed high testosterone levels (See Table 1).
The provisional diagnosis was PAIS in this patient. There was
no family history of DSD and/or adrenal insufficiency. At age 4,
he had no evidence of adrenal insufficiency on formal short
synacthen testing.
Functional analyses
The p.Y25C variant of NR5A1 showed impaired transcriptional
activation of the Cyp11a promoter (Fig. 2a). In a substantial
proportion of cells, p.Y25C mutant SF-1 showed partially
impaired nuclear localization (Fig. 2b).
Discussion
Currently, over 50 different NR5A1 mutations have been
reported in humans.15,17,18 These mutations include missense
mutations, nonsense mutations caused by nucleotide deletions
and duplications, a 3 Mb deletion, a 970 kb deletion and a dele-
tion in exon 2 and 3. The degree of gonadal dysgenesis and
underandrogenization varies from mild to severe, with three
mutations also causing adrenal failure. All cases of 46,XY DSD
(except for two homozygous mutations) are heterozygous for
the mutation, indicating that SF-1 dosage is critical.8,9 The
varying locations of the different NR5A1 mutations suggest
the absence of a mutation hot spot and the lack of a founder
effect.
In our study of 17 patients with presumed androgen insensi-
tivity but with no AR mutation, one patient was found to have
a de novo mutation in NR5A1 which caused reduced SF-1 tran-
scriptional activation with partially impaired nuclear localization
in a significant proportion of transfected cells. To our knowl-
edge, this is the first patient described with a NR5A1 loss-of-
function mutation and elevated testosterone shortly after birth.
It is known that within 24 h after birth and then at 1–2 months
of life, there are physiologically high levels of testosterone that
can be as informative as the hCG stimulation test.19 Despite one
of our patient’s levels being taken outside this period, his level
was still high. Although NR5A1 mutations are known to cause
dysgenetic testes and/or impaired androgen synthesis, there have
been previously published cases of affected 46, XY infants with
normal testosterone levels.2,20 In the first described case, the
baby had a perineal urogenital sinus, a genital tubercle measur-
ing 12 mm in length, palpable gonads (12 9 5 mm) in the
bilateral inguinal regions and a hypotropic scrotum or corruga-
tion of major labia.2 The phenotype in the second case described
may be due to other genes in addition to NR5A1 contained in
the deletion of chromosome 9q33.3 identified in this child. The
phenotypically female infant was noted to have clitoromegaly at
10 weeks of age. She was then found to have a shallow vaginal
entrance with a 1 ml gonad palpable in the left labium. Abdomi-
nal ultrasonography showed no uterus or Mu¨llerian structures.20
Recently, two more NR5A1 cases with normal testosterone at
infancy were published in a cohort study. One patient had scro-
tal hypospadias, bilateral cryptorchidism and no Mu¨llerian struc-
tures. Another had scrotal hypospadias, intraabdominal testes
and presence of Mu¨llerian duct remnants.15 Our patient’s phe-
notype suggests that there was a sufficient amount of anti-
Mu¨llerian hormone (AMH/MIS) for Mu¨llerian regression and
testosterone for Wolffian development. There must have been
low dihydrotestosterone or dihydrotestosterone insensitivity,
Fig. 1 The c.74A>G alteration in this patient causes
a tyrosine to cysteine change at codon 25 (p.Y25C).
This amino acid is highly conserved and affects a
codon located within the first zinc finger DNA-
binding domain (DBD).
Table 1. Hormone results at two periods shortly after birth
13 days old
1 month + 18
days old
Testosterone (nM) 108↑ (RI 31–10)2 25 ↑(RI 18–166)2
Dihydrotestosterone (nM) 42↑ (RI 017–21)16 53 ↑ (RI 04–29)16
LH (IU/l) 79↑ (RI 27–78)2 12 (RI 012–48)2
FSH (IU/l) 39↑ (RI 17–35)2 16 (RI 06–55)2
RI, Reference Interval.
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however, at least during the critical period of external genitalia
formation (between 8 and 14 weeks gestation).12,21 Elevated tes-
tosterone in this patient is unexpected; however, the mechanisms
underlying the variable effect of NR5A1 mutations are still not
clearly understood. This is illustrated by the previously
mentioned study of a baby with normal testosterone levels
whose sibling (a 46, XY female) had the same mutation but was
less virilized and had low testosterone production.2 It therefore
appears that differences in phenotypes and Leydig cell function
exist even within a family with the same mutation and other
genetic or environmental factors may affect testosterone produc-
tion.2 It may be that in some cases disruption of SF-1 is associ-
ated with functional androgen resistance22 or altered Leydig cell
maturation and hyper-responsiveness to postnatal LH stimula-
tion. These possible explanations for the relatively high androgen
levels found here are speculative, but it will be of great interest
to know whether NR5A1 changes can be found in further sys-
tematic studies of children with high or normal androgen
concentrations who have been diagnosed as having AR negative
PAIS.
This case illustrates that mutations of NR5A1 may be an
important genetic cause in 46, XY DSD patients with a range of
testosterone levels, and all patients negative for AR mutations
should be considered for NR5A1 gene analysis even if testoster-
one biosynthesis is elevated. It will be of interest to note whether
the capacity to produce testosterone is maintained to enable
normal progression of puberty and development of secondary
sexual characteristics. Initial evidence suggested that with
increasing age, there will be decreasing testosterone as one study
found that 4% of otherwise healthy men with unexplained azoo-
spermia carried mutations in NR5A1 and that these men may
also be at risk of endocrine dysfunction with failing testosterone
with increasing age.13 However, recently, two studies presented
in total four 46,XY patients with mutations in NR5A1 who
entered puberty spontaneously with normal testosterone
levels.18,23 It will be interesting to document future testosterone
levels in these patients to elucidate whether there is premature
failure of testosterone production and to determine their fertility
potential.
Both parents were found to be negative for the mutation
found in their son. De novo mutations have been documented in
the majority of reported NR5A1 cases where the mode of inheri-
tance is known.24 Interestingly, around 30% are documented to
be inherited from the mother in a sex-limited dominant fashion,
in that mothers may carry the mutation without ovarian
dysfunction and pass it onto sons who are affected (mimicking
X-linked inheritance).17 For the remainder, the inheritance is
unknown, autosomal recessive or from their phenotypically nor-
mal fathers in rare instances.15,24 Thus, the absence of a family
history should not detract from the possibility of NR5A1 muta-
tions.
The finding of an NR5A1 mutation is important in the man-
agement of an infant with 46,XY DSD, as this diagnosis has
implications for genetic counselling and future treatment. Unlike
AIS, children with NR5A1 mutations should theoretically
respond to normal levels of exogenous testosterone. It is unclear
whether 46,XY DSD patients with NR5A1 mutations with the
presence of testes and raised as males will be at risk of gonadal
malignancy; however, it is likely that they will have progressive
testicular changes over time with implications for fertility.11,13
This knowledge will influence sex assignment and family plan-
ning. As patients can have adrenal insufficiency, this knowledge
will prepare patients and allow health professionals to initiate
closer evaluation. Mutation carrier mothers and sisters of 46,XY
DSD patients may also be at risk of premature ovarian insuffi-
ciency and possibly adrenal insufficiency.25 Females might also
appear to be asymptomatic but pass on the mutation with the
potential of having 46,XY DSD children. Being aware of these
possibilities will help with genetic counselling and prepare the
families and allow closer follow-up.
For the remainder of 46,XY DSD patients still without
a molecular diagnosis other genes should be investigated.
(a)
(b)
Fig. 2 (a) Assays showing activation of a Cyp11a1 promoter by wild-
type (WT) SF-1 and impaired transcriptional activity by the p.Y25C
mutant. Relative luciferase activity was measured and expressed as fold
activation above baseline (empty vector). Results are shown as the
mean ± SEM of three independent experiments, each performed in
triplicate. (), empty vector; WT, wild-type; p.G35E, a known loss-of-
function mutation. (b) Immunocytochemistry to show cellular
localization of SF-1 linked to GFP. Wild-type (WT) SF-1 shows strong
nuclear localization, whereas the p.Y25C mutant GFP-SF-1 construct
shows partially impaired nuclear localization in a proportion of cells.
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Evidence suggests that molecular analysis of SRD5A2 for
5a-reductase deficiency and HSD17B3 for 17b-hydroxysteroid
dehydrogenase-3 deficiency are important as endocrine testing
are potentially unreliable.26,27 This might also be the case with
Leydig cell hypoplasia caused by inactivating mutation of the
LH receptor.28 With the rapid advancements in genome
sequencing, it is likely that simultaneous testing for all these
genes will become more common in future.
In summary, we identified one novel NR5A1 mutation in an
Australasian cohort of 17 46,XY DSD patients who had previ-
ously been assessed for AR mutations. As AR mutations are only
detected in 136–28% of patients with clinical diagnosis of PAIS,
it is important for other diagnoses, including NR5A1 mutations,
to be considered.3,4 The high testosterone measurement in
this case highlights the biochemical variability associated with
SF-1/NR5A1 mutations.
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